Reneo Pharmaceuticals Appoints Roshawn Blunt to its Board of Directors
Retrieved on:
Tuesday, August 2, 2022
Northwestern University, Johnson & Johnson, Mitochondrion, GLOBE, Â, Degenerative disease, U.S. Securities and Exchange Commission, Princeton University, Miller Children's Hospital, Private Securities Litigation Reform Act, Board, Adenosine triphosphate, Amgen, Princeton School of Public and International Affairs, Hospital, Gene, Policy, Roshawn Franklin, MBA, Security (finance), Communication, Patient, ATP, Nasdaq, LLC, Boston Consulting Group, International relations, Kellogg School of Management, Founder, Pharmaceutical industry
IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the companys Board of Directors.
Key Points:
- IRVINE, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic mitochondrial diseases, today announced the appointment of Roshawn Blunt to the companys Board of Directors.
- Roshawn is an accomplished leader within the biopharma industry, said Mike Grey, Executive Chairman of Reneo Pharmaceuticals.
- I am thrilled to join the Reneo Board, said Ms. Blunt.
- Reneo is an extraordinary company with a novel drug that has the potential to treat a number of mitochondrial diseases.